Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Invested Capital (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Invested Capital for 11 consecutive years, with $196.1 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 34.59% to $196.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $196.1 million through Dec 2025, down 34.59% year-over-year, with the annual reading at $196.1 million for FY2025, 34.59% down from the prior year.
  • Invested Capital hit $196.1 million in Q4 2025 for Voyager Therapeutics, down from $219.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $340.9 million in Q1 2024 to a low of $59.0 million in Q4 2022.
  • Historically, Invested Capital has averaged $188.6 million across 5 years, with a median of $197.6 million in 2023.
  • Biggest five-year swings in Invested Capital: plummeted 47.41% in 2021 and later skyrocketed 300.41% in 2023.
  • Year by year, Invested Capital stood at $95.1 million in 2021, then crashed by 37.91% to $59.0 million in 2022, then surged by 300.41% to $236.3 million in 2023, then grew by 26.84% to $299.8 million in 2024, then tumbled by 34.59% to $196.1 million in 2025.
  • Business Quant data shows Invested Capital for VYGR at $196.1 million in Q4 2025, $219.8 million in Q3 2025, and $243.9 million in Q2 2025.